Date:6/3/2011

litis (1), depression (1) and grade 4 elevation of CK (1). Pharmacokinetic analysis of the AUC ratios demonstrated that actual imatinib AUC levels were significantly higher than predicted (P=0.036), but there was no difference between actual and predicted AUC for the active metabolite (P=0.441), suggesting the anti-retroviral regimens influenced imatinib metabolism. Levels of CCL5, IFNg, IL-6 and FGF-b correlated with response in a pilot study; however, none of these growth factors predicted response in this larger study. Conclusions: Imatinib has activity in AIDS-related Kaposi's sarcoma. The potential interactions with antiretroviral drugs did not correlate with increased toxicity. Thirty percent of patients showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest this regimen is well tolerated and may be an alternative to cytotoxic chemotherapy for some patients with AIDS-related KS.

---

Charles Kunos, MD, PhD
Title: Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer.

Friday June 3, 2:00 PM to 6:00 PM

Abstract (http://abstract.asco.org/AbstView_102_74945.html) : Background: This on-going clinical trial assesses the safety and clinical activity of 3x weekly intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) co-administered with 1x weekly intravenous cisplatin and daily pelvic radiation in patients with locally advanced cervical and vaginal cancer. 3-AP potently inhibits ribonucleotide reductase and clinically is being evaluated as a chemoradiation sensitizer. Here, we report the preliminary toxicity and response data. Methods: Patients with stage IB2 to IVB cervical cancer (n = 12) or stage II to IV vaginal cancer (n = 2) underwent 2-hour 3-AP infusions (25 m
'/>"/>

Contact: Alicia Reale alicia.reale@uhhospitals.org 216-533-0685 University Hospitals Case Medical Center Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. BUSM study finds older men more likely to lose the ability to orgasm due to gabapentin
2. Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds
3. Safer sex: Study examines sexual communication in transgender community
4. High-Risk Surgeries Getting Safer: Study
5. Study: Children of divorce lag behind peers in math and social skills
6. New grant to study how pediatric brain tumor, ependymoma, develops
7. USC study locates the source of key brain function
8. Penn study identifies genes that may help predict response to BRAF inhibitors for advanced melanoma
9. Children With ADHD More Prone to Substance Abuse: Study
10. Study finds fire stations contaminated with MRSA
11. New study looks at disconnect between medical and lay expertise